Clinical Trial

the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 29, 2024 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-05-08.
Trial Details
NCT Number NCT05864170
Lead Sponsor Shenzhen Hemogen
Conditions β-thalassemia
Enrollment 3 participants
Start Date 2022-05-27
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-29